Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes

Background: Tigecycline is a therapeutic option for carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Our aim was to evaluate the impact of the tigecycline’s minimum inhibitory concentration (MIC) in the outcome of patients with CP-Kp bacteraemia treated with tigecycline monotherapy. Methods: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadimitriou-Olivgeris, Matthaios, Bartzavali, Christina, Nikolopoulou, Alexandra, Kolonitsiou, Fevronia, Mplani, Virginia, Spiliopoulou, Iris, Christofidou, Myrto, Fligou, Fotini, Marangos, Markos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699267/
https://www.ncbi.nlm.nih.gov/pubmed/33228012
http://dx.doi.org/10.3390/antibiotics9110828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699267/
https://www.ncbi.nlm.nih.gov/pubmed/33228012
http://dx.doi.org/10.3390/antibiotics9110828

Ejemplares similares